Clin Microbiol Infect:无创通气患者使用喷雾抗生素治疗临床研究推荐

2017-04-19 MedSci MedSci原创

喷雾抗生素在无创性机械通气患者中的使用临床上并不少见,但是其有效性及安全性缺少有效的临床证据。Clin Microbiol Infect杂志中一篇文章对这一临床应用进行了研究报道。由于抗生素的滥用,抗生素耐药性的增加以及新药的缺乏,使得我们急需一种能加强抗生素有效性的方法。因此,作为一种潜在的优化治疗方式的喷雾抗生素,尤其是其在治疗多耐药(MDR)病原体感染患者中的潜在价值,引起了人们极大的兴趣。

喷雾抗生素在无创性机械通气患者中的使用临床上并不少见,但是其有效性及安全性缺少有效的临床证据。Clin Microbiol Infect杂志中一篇文章对这一临床应用进行了研究报道。

由于抗生素的滥用,抗生素耐药性的增加以及新药的缺乏,使得我们急需一种能加强抗生素有效性的方法。因此,作为一种潜在的优化治疗方式的喷雾抗生素,尤其是其在治疗多耐药(MDR)病原体感染患者中的潜在价值,引起了人们极大的兴趣。

基于推荐评估的等级、发展及评估的(GRADE)方法论,针对喷雾抗生素在无创机械通气的成年患者中的使用,通过对现存文献进行回顾和进行了Meta分析后,欧洲临床微生物学和传染病学会的建议书提出了一些建议。

一些文章不推荐喷雾抗生素在临床的使用,主要是考虑到其疗效不显着及明显副作用,但是这些结论缺乏有力的研究证据。临床实践急需高质量的证据来支撑。专家组急需进行一项临床随机试验,使用喷雾抗生素来代替传统方法,治疗多耐药病原体感染的肺炎。

原始出处:

Rello J, Solé-Lleonart C, Rouby JJ,et al.Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper from the European Society of Clinical Microbiology and Infectious Diseases.Clin Microbiol Infect. 2017 Apr 13. pii: S1198-743X(17)30219-7. doi: 10.1016/j.cmi.2017.04.011.

本文系梅斯医学(medsci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-05-15 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-10-28 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1767095, encodeId=e5a91e6709576, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Oct 01 19:16:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917440, encodeId=8ea4191e4401c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 15 18:16:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084200, encodeId=f456208420042, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Oct 28 10:16:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857432, encodeId=2dbe185e4326d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 07 01:16:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345205, encodeId=37d0134520534, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495693, encodeId=fe1014956938e, content=<a href='/topic/show?id=aa1e58914c2' target=_blank style='color:#2F92EE;'>#无创通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58914, encryptionId=aa1e58914c2, topicName=无创通气)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e489186998, createdName=yhy100203, createdTime=Fri Apr 21 05:16:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]

相关资讯

盘点:机械通气有了,那么无创通气优势更大吗?

无创通气可以避免气管插管和气管切开引起的很多并发症,近年来得到了广泛的推广和应用。尽管很多随机对照试验证实无创通气治疗慢性阻塞性肺疾病和心源性肺水肿导致的急性呼吸衰竭的疗效肯定,但是无创通气在急性低氧性呼吸衰竭(AHRF)中的应用却存在很多争议。迄今为止,仅有少量的研究表明无创通气可以降低急性肺损伤患者气管再插管率,尚无足够的资料显示无创通气可以作为 ARDS 导致的低氧性呼吸衰竭的常规治疗方

无创通气可降低新生儿呼吸窘迫综合征的治疗成本及住院时间

据在2016 AAP全国会议及展览的一项研究结果显示,与气管插管治疗相比,使用无创通气治疗早产儿呼吸窘迫综合征的医疗费用较低,住院时间较短。研究人员收集了1997-2012年国家医疗保健费用和利用KID的数据来确定无创通气和气管插管在新生儿呼吸窘迫综合征患儿中的使用率,以及气管插管的预测,留置时间和平均成本。最终确定了595254例新生儿呼吸窘迫综合征,其中12%的患儿仅用无创通气治疗,51%的患

头罩式无创通气!看起来有点酷

无创通气可以避免气管插管和气管切开引起的很多并发症,近年来得到了广泛的推广和应用。

Crit Care Med:无创通气会增加老年肺炎患者的死亡率吗?

本研究的目的是确定现实世界中,机械通气和肺炎患者结局间的关系。 我们对医疗保险受益人(年龄>64岁)进行了一项回顾性队列研究,这些患者是在2010至2011年间进行机械通气的肺炎患者,来自美国2757家急性护理医院。干预是无创通气与有创机械通气。 主要结果是30天死亡率,医疗保险报销作为次要结果。考虑到与使用无创通气相关的不可测量的混杂因素,我们使用了一个工具变量,高无创性通气使用医院

Thorax:无创通气改善不伴有OSA肥胖低通气综合征患者呼吸功能

由此可见,NIV比改善生活方式更能有效的改善日间PaCO2、嗜睡和睡眠指标。此外,需要长期的前瞻性研究来确定NIV是否能够减少医疗资源的利用、心血管事件和死亡率。

JAMA:LISA法或是预防早产儿支气管肺发育不良及死亡的更佳策略

目前用于预防早产儿支气管肺发育不良(BPD)的无创通气策略有多种,但是尚未确定最佳的无创通气策略。本研究旨在对比7种无创通气策略的效果,包括仅进行经鼻持续气道正压通气(CPAP),气管插管-气管内滴入肺表面活性物质(INSURE)、微创法肺表面活性物质注入(LISA),无创正压通气,表面活性剂雾化吸入,通过喉罩通气吸入表面活性剂,和机械通气。 研究人员检索了截止至2016年6月MEDLINE